1073371-77-3Relevant articles and documents
CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.02·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE
-
Page/Page column 57, (2021/10/15)
Disclosed are crystalline forms of Compound (I). Compound (I) is useful as an anti-thromboembolic agent in the treatment of cardiovascular diseases.
Heterocyclic compound and application thereof
-
Paragraph 0296-0300, (2021/02/10)
The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound shown as a formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound can be used as an FXIa inhibit
Alkoxy pyridone compound as well as preparation method and application thereof
-
Paragraph 0203-0205, (2020/12/15)
The invention belongs to the field of medicinal chemistry, specifically, the invention relates to a series of inhibitors of factor XIa (FXIa for short) with a novel structure as well as a preparationmethod and an application thereof. The structure is shown as the following general formula (I). These compounds or stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvatesor pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used to treat or/and prevent related diseases mediated by factor XIa (FXIa for short).